carbendazim has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camden, JB; Dexter, DL; Hao, D; Mangold, GL; Marty, J; Moore, RV; Rizzo, JD; Stringer, S; Von Hoff, DD; Weitman, SD | 1 |
| Camden, JB; Davidson, K; Hammond, LA; Izbicka, E; Lawrence, R; Von Hoff, DD; Weitman, S | 1 |
2 other study(ies) available for carbendazim and B16 Melanoma
| Article | Year |
|---|---|
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Carbamates; Cell Division; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Leukemia P388; Male; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Rats; Rats, Inbred F344; Therapeutic Equivalency; Tumor Cells, Cultured | 2002 |
Exploring the mechanisms of action of FB642 at the cellular level.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Carbamates; Cell Cycle; Cell Division; Colorectal Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genes, p53; Humans; Leukemia; Leukemia, Experimental; Male; Melanoma, Experimental; Mice; Neoplasm Proteins; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |